ProCE Banner Activity

BCMA-Targeted CAR T-Cells ± Cyclophosphamide in Relapsed/Refractory Multiple Myeloma: Phase I Study

Slideset Download
Conference Coverage
BCMA-CART with or without cyclophosphamide lymphodepletion demonstrates promising clinical activity in heavily pretreated patients with MM.

Released: December 12, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology